NCT05542849已完成4 期
The Efficacy and Tolerability of Acarbose in Healthy Individuals: A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
AgelessRx1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2022年8月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Monophasic glucose response
研究概览
简要总结
A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Any ethnicity
- •Interest in taking Acarbose off-label
- •Approved by the AgelessRx Medical team to take Acarbose
- •Willing and technically able to use and operate a CGM
- •Own a CGM-compatible phone
- •Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable
- •Adequate cognitive function to be able to give informed consent
排除标准
- •Diabetes of any type
- •Taking metformin or any other glucose lowering medication
- •Any uncontrolled endocrine disorder (thyroid, pancreatic, adrenal, etc...)
- •Active malignancy of any kind
- •Clinically relevant renal or kidney disease or dysfunction
- •History of eating disorder
- •Taking any medication, or has any medical condition that might interfere with the action of acarbose of the CGM sensor
研究组 & 干预措施
Arm A
Experimental
干预措施: Acarbose Tablets 50mg (Drug)
Arm B
Experimental
干预措施: Acarbose Tablets 50mg (Drug)
结局指标
主要结局
Monophasic glucose response
时间窗: 120 minutes per phase, recorded on 4 separate occasions over 2 weeks.
Blood glucose (mg/dl) response following high carbohydrate intake
次要结局
- Tolerability of Side Effect(Recorded on 4 separate occasions over 2 weeks.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Glucose Reduction by Early Acarbose Treatment in Basal InsulinDiabetes Mellitus, Type 2NCT00970528Bayer124
已完成
3 期
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary CareDiabetes MellitusNCT01010100Bayer204
已完成
4 期
Acarbose Cardiovascular Evaluation TrialImpaired Glucose ToleranceType 2 Diabetes Mellitus (T2DM)Acute Coronary SyndromeCoronary Heart DiseaseNCT00829660University of Oxford6,526
已完成
不适用
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular DiseaseDiabetes MellitusNCT01167231Bayer3,310
已完成
3 期
Acarbose and Secondary Prevention After Coronary StentingGlucose Metabolism DisordersCoronary Artery DiseaseNCT00221156Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan300